RAMAT GAN, Israel--(BUSINESS WIRE)--LabStyle Innovations Corp. (OTCQB: DRIO), developer of a diabetes-related, cloud-based mobile health (mHealth) platform and the Dario™ blood glucose monitoring system for patients and caregivers, announces that a presentation delivered by Executive Chairman Dr. Oren Fuerst at Cleveland Clinic’s 2013 Medical Innovation Summit highlighting LabStyle’s latest developments is now available at www.mydario.com and at http://www.slideshare.net/oren68/dario-investors-october-15-cleveland-adb.
Held October 14-16 in Cleveland under the theme “Finding Balance Through Innovation. Obesity, Diabetes & the Metabolic Crisis,” the Summit brought together more than 1,000 executives, investors, entrepreneurs and clinicians to examine one of the most critical issues in healthcare today, namely how to combat the obesity epidemic.
Dr. Fuerst showcased how LabStyle is seeking to make Dario a focal point for the comprehensive management of diabetes information, including a diabetes management software platform that covers monitoring to therapy and is designed to drive patient insight into how to better manage their diabetes. The Dario app will consider various information patterns like food intake, blood glucose levels, exercise and others. Dario received CE mark approval this past September.
“Our goal is for the Dario software system to become the centerpiece in a new era of interconnected devices and services that provide healthier and better life for the diabetic patients worldwide,” said Dr. Fuerst. “Dario is designed to be a software-driven, comprehensive data-management system with sophisticated insight and analytical tools constantly attuned to each individual patient, and to enable integration with various devices including most notably the modern, user-friendly Dario glucose monitoring device.”
“It was a privilege to speak to the esteemed group of attendees at the 2013 Medical Innovation Summit about our fresh and comprehensive approach of managing diabetes and proactive care,” he added. “Following our initial roll out of the Dario app and device, we will also seek to develop additional mHealth devices and services leveraging our technologies in the future, both on our own and potentially in partnership with others.”
About Dario
Simple, personal and feature-rich, Dario is poised to revolutionize the self-monitoring of blood glucose (SMBG). Designed mainly to help type 1 and insulin-dependent type 2 diabetics better manage their lives, Dario is an integrated device and software system that is designed to facilitate regular testing and the capture and sharing of critical data, which in turn could result in better blood glucose control, improved health and lower healthcare expenditures.
Dario’s contemporary design seeks to complement a user’s active lifestyle. The compact all-in-one device contains a lancet to obtain a small drop of blood, a strip dispenser and a glucose reader adaptor to hold the strip and interface with a smartphone. The adaptor plugs into the smartphone’s audio jack, and combines with a free app and internet-based data services for unmatched functionality.
The Dario app will be able to be used independently of the Dario device and regardless of the patient’s glucose meter, and later this year will be available in Europe as a free download from the App Store.
The Dario app will allow users to enter information about food intake (for comparison with a database on carbohydrates, calories and more), exercise and physical activity, and to use a proprietary insulin calculator to determine the correct dose. Self-reported data along with blood glucose results are analyzed and stored, and real-time, historical or tailor-made data can then be shared with physicians, nurses, dieticians, caregivers and others.
Dario provides alerts for abnormally high or low glucose levels, while logs, charts and graphs provide an intuitive and clear display of data, all of which is saved via cloud and syncs automatically with the app and web portal. Frequent testing with Dario will be encouraged by multiple reminder systems, virtual rewards and online competitions.
Recognizing that regular SMBG is but one element in managing diabetes, www.mydario.com allows users to participate in a growing online community of fellow diabetics, share stories, exchange tips and support one another. LabStyle is committed to keeping Dario fresh and plans for regular updates and improvements, including new functionality and new web portals.
About LabStyle Innovations
LabStyle Innovations Corp. is developing and commercializing a comprehensive data-management system with sophisticated analytical tools connected to multiple access devices, including a blood glucose monitor used with smartphones such as iPhones, Androids and other mobile devices. LabStyle’s initial product is Dario™, an integrated medical device and software system addressing the market for diabetic SMBG, a market that is estimated to exceed $10 billion worldwide. Dario is a comprehensive, patent-pending and user-friendly system that combines an all-in-one medical device consisting of an integrated lancet (to obtain a blood sample), a device-specific disposable test strip cartridge and a smartphone-driven glucose reader adaptor, together with a smartphone app and cloud-based data services. LabStyle is also developing other services and products for the global diabetes-management market. For more information, please visit www.mydario.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the presentation referred to herein contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results (including the results of the Dario software and product launch and the Company’s development plans discussed herein) and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Key Words: Digital Health; eHealth; mHealth; Mobile; Mobile Health; Diabetes; Software; Mobile; Medical Device; Life Sciences